CPHI 2025: directing AI-driven innovation to harness Europe’s data edge

📊 Healthcare News Analysis: Our editorial team has analyzed recent developments from pharmaceutical-technology.com in the Healthcare sector. This report covers key insights related to medical treatment, surgery, prescription and emerging industry trends that professionals should monitor closely.

Industry observers in Healthcare are monitoring emerging trends closely. According to reports that share

Copy Link
Share on X
Share on Linkedin
Share on Facebook

Biocat’s Monserrat Dabban urged stakeholders in European biopharma to see innovation through AI-driven data analytics as the route to future competitive success. Sources indicate that credit: Ivan Marc / Shutterstock.com. Europe’s biopharma stakeholders should seek innovation through AI to meet the challenges of treatment resistance, drug affordability, and a creeping patent cliff, channelling the continent’s health data to catch up to more competitive industries in the US and China.

This was the view Montserrat Dabban outlined in her keynote address at the 2025 CPHI conference, which took place on 28–30 October in Frankfurt. Dabban is the director of strategic foresight and international relations at Biocat, a public-private entity to support the healthcare ecosystem in Catalonia, Spain. Go deeper with GlobalData

Reports Smart Pharma – Thematic Research
Reports Artificial Intelligence (AI) in Healthcare – Thematic Research

Go deeper with GlobalData
The gold standard of business intelligence.

Find out more
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms. Find out more
She stated that stakeholders in the European biopharma industry could find innovative solutions to challenges in several key areas by using AI to leverage the vast amounts of data collected by health systems for drug discovery and improved trial design. Dabban identified several key challenges faced by the global biopharma industry today, including logistical ones like scaling up cell and gene therapies, improving clinical trial speeds, drug affordability, as well as the uncertainties of supply chain resilience, sustainability, and pandemic preparedness. Sources indicate that meanwhile, she noted the industry faces an oncoming wave of drug patent expiries, risking billions of dollars in total annual revenues: “Pipelines are thinning … pipeline growth slowed.”
Additionally, current research trends have a lopsided focus on development in metabolic, immunological, and oncological diseases at the expense of other indications.

GlobalData Strategic Intelligence US Tariffs are shifting – will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence
To avoid the pitfalls of what Dabban termed “therapeutic saturation” — too many molecules developed for too few targets — she said all stakeholders in European biopharma must cooperate in addressing several key domains: aging populations, brain health, cancer, antimicrobial resistance, health equity, and rare disease.

To do so, she pointed to upscaling the utilisation of Europe’s extensive health databases. Dabban said that improved use of data from wearable devices can open the door to digital phenotyping, improved biomarkers, and centralised endpoints in neurological trials. For example, in oncology, she suggested exploring adaptive trials and federated analytics so that data from multiple sources can be analysed without needing to be centralised. According to reports that but Dabban told attendees that a vast data store was “useless if it’s not processed, and we need technology for that”.

Sources indicate that hence, AI would prove key to effectively processing health data as a means to developing faster clinical trials with more focussed endpoints, she stated. Sources indicate that “We are at a crossroads. Sources indicate that we have to seize the moment for Europe … we have to expect more competition, but also more breakthroughs,” Dabban concluded. Sign up for our daily news round-up!

Give your business an edge with our leading industry insights. Sign up
Pharmaceutical Technology Excellence Awards – The Benefits of Entering
Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact.

By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now Share

Copy Link
Share on X
Share on Linkedin
Share on Facebook

Reports Smart Pharma – Thematic Research
Reports Artificial Intelligence (AI) in Healthcare – Thematic Research

Go deeper with GlobalData
The gold standard of business intelligence. Find out more
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.

Experts suggest this represents a significant moment for the Healthcare sector, with implications extending beyond immediate stakeholders.

— Based on reporting from pharmaceutical-technology.com

💡 Key Industry Insights

Healthcare innovation is accelerating with advances in telemedicine, personalized medicine, and medical technology.

Specifically regarding medical treatment, market observers note continuing evolution in service delivery, pricing models, and customer engagement strategies that merit close attention from industry stakeholders.

Market Impact: These developments in medical treatment may significantly influence market dynamics. Industry experts recommend monitoring these trends closely for strategic planning purposes.

Analysis Note: This comprehensive overview synthesizes current market intelligence from pharmaceutical-technology.com regarding surgery and related sectors. Stay informed about ongoing developments in this rapidly evolving landscape.